EUR-Lex Access to European Union law
This document is an excerpt from the EUR-Lex website
Document 52015XC0505(04)
Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 to 28 February 2015 (Published pursuant to Article 13 or 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)
Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 to 28 February 2015 (Published pursuant to Article 13 or 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)
Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 to 28 February 2015 (Published pursuant to Article 13 or 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)
OJ C 148, 5.5.2015, p. 1–3
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
5.5.2015 |
EN |
Official Journal of the European Union |
C 148/1 |
Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 to 28 February 2015
(Published pursuant to Article 13 or 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council (1))
(2015/C 148/01)
— Issuing of a marketing authorisation (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted
|
Date of the decision |
Name of the medicinal product |
INN (International Non-Proprietary Name) |
Holder of the marketing authorisation |
Number of the entry in the Community Register |
Pharmaceutical form |
ATC code (Anatomical Therapeutic Chemical Code) |
Date of notification |
|
10.2.2015 |
Suvaxyn CSF Marker |
Live Recombinant E2 gene deleted Bovine Viral Diarrhoea Virus containing Classical Swine Fever E2 (CP7_E2alf) |
Zoetis Belgium S.A. Rue Laid Burniat 1, 1348 Louvain-la-Neuve, Belgique |
EU/2/14/179 |
Lyophilisate and solvent for suspension for injection |
QI09AD04 |
12.2.2015 |
Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:
|
The European Medicines Agency |
|
30, Churchill Place, Canary Wharf |
|
UK - LONDON E14 5EU |
(1) OJ L 136, 30.4.2004, p. 1.